IFPW's Anti-Counterfeiting Policy

Counterfeiting is not a victimless crime. It isn’t an offense against trademarks or the balance sheets of pharmaceutical companies. Counterfeit drugs hurt people and the victims are most often people who need real, quality drugs the most: cancer patients, AIDS patients, and people being treated for heart disease (taken from a WebMD report).

At its September 2004 meeting, IFPW’s Directors adopted a “Zero Tolerance” policy on counterfeit pharmaceutical products: IFPW will impose the most stringent, lawful sanctions that are at its disposal against any company or entity that willfully or negligently engages in the production, distribution or sale of counterfeit pharmaceutical products.

IFPW is a Participant in the World Health Organization's International Medical Products Anti-Counterfeiting Taskforce (IMPACT).  Click here to learn more about the program, IFPW's involvement in IMPACT and to participate in IMPACT Working Groups and/or IFPW IMPACT Committees.